CASP9 and autoimmune thrombocytopenic purpura: Accordingly, it was hypothesized that CASP9, C1orf109, and AMD1 might be harnessed as therapeutic targets and provide a rationale for early diagnosis and treatment in patients with primary refractory ITP.